Clinical Trials
14 trialsNCT04541108 2026-05-22
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
Phase EARLY_PHASE1 Active not recruiting
NCT07459283 2026-03-10
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
NCT06645808 2025-12-29
VARTUTRACE
Var2 Pharmaceuticals
Phase EARLY_PHASE1 Recruiting
NCT06413095 2024-05-14
PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS
Presage Biosciences
Phase EARLY_PHASE1 Completed
NCT06171282 2023-12-14
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Recruiting
NCT06117878 2023-11-07
Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04074564 2023-10-23
MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma
HRYZ Biotech Co.
Phase EARLY_PHASE1 Unknown
NCT05961111 2023-07-27
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Recruiting
NCT05886075 2023-06-02
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Unknown
NCT05860374 2023-05-16
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Unknown
NCT05851456 2023-05-09
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Unknown
NCT04891718 2022-07-08
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Presage Biosciences
Phase EARLY_PHASE1 Withdrawn
NCT04864821 2021-05-06
Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT00743353 2009-02-02
K5
Siemens Molecular Imaging
Phase EARLY_PHASE1 Completed